AlbA-DCA is a conjugate formed by the attachment of Albiziabioside A to a dichloroacetate acid subunit. It can induce a marked increase in intracellular ROS and alleviate the accumulation of lactic acid in the tumor microenvironment, and also selectively kills cancer cells and induce apoptosis.

AlbA-DCA exhibits the cytotoxicity against the MCF-7 cells, HCT116 cells, A375 cells, 4T1 cells, HBMEC cells and LO2 cells (IC50s: 0.43 μM, 3.87 μM, 3.78 μM, 1.31 μM, 38.20 μM and 53.14 μM). AlbA-DCA (2 μM; 24 hours) treatment induces apoptotic cell death in MCF-7 cells. AlbA-DCA (2 μM; MCF-7 cells) treatment could significantly up-regulate the expression of cytochrome c and down-regulate the expression of anti-apoptotic protein Bcl-2. AlbA-DCA significantly enhances the expression of caspase-9.

AlbA-DCA (2 mg/kg; subcutaneous injection; every 2 days; for 2 weeks; nude mice) treatment displays antitumor efficacy and almost completely suppresses tumor progression, and no mouse deaths and no significant changes in body weight are observed. AlbA-DCA has no obvious toxicity of liver and kidney and no major abnormality is observed in the heart, liver, spleen, lung, and kidney.

T13538

C43H67Cl2NO12

860.9

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years